ArticleCancer medicine2026
Association Between Red Blood Cell Distribution Width-To-Albumin Ratio and Breast, Colorectal, Lung, and Prostate Cancers.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
- Reference Range of Red Cell Distribution Width-to-Albumin Ratio in Healthy US Adults: A Cross-Sectional Study.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer remains a leading cause of global morbidity and mortality, underscoring the need for accessible biomarkers for early detection and risk stratification. The red blood cell distribution width-to-albumin ratio (RAR) integrates inflammation and nutritional markers often dysregulated in cancer. We evaluated RAR's association with a recent diagnosis (≤ 1 year) of breast, colorectal, lung, and prostate cancer in a representative US population.
methodsUsing National Health and Nutrition Examination Survey data (2005-2018), we conducted a cross-sectional analysis of adults with recent diagnoses (≤ 1 year) of a single primary cancer. Propensity score matching balanced cases and cancer-free comparisons by age, sex, and race. Weighted logistic regression assessed associations between a 1-unit RAR (%dL/g) increase and cancer presence, reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs).
resultsThe analysis included 48 breast, 31 colorectal, 19 lung, and 77 prostate cancer cases, along with their matched comparisons. A 1% dL/g increase in RAR was significantly associated with higher odds of breast (adjusted OR 1.62, 95% CI 1.17-2.24), colorectal (adjusted OR 1.56, 95% CI 1.01-2.40), and lung cancer (adjusted OR 1.95, 95% CI 1.44-2.66). No significant association was observed for prostate cancer (adjusted OR 1.05, 95% CI 0.69-1.59).
conclusionRAR is significantly associated with a recent diagnosis of breast, colorectal, and lung cancers, but not prostate cancer. These findings suggest RAR may reflect cancer-associated systemic alterations, warranting further prospective study to validate its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.